Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 14/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3018389 | 0.90 | KCNH2 (0.49) | KCNH2 | |
| SCHEMBL13213622 | 0.83 | KCNH2 (0.49) | KCNH2 | |
| Hydrochloric Acid SCHEMBL3027004 | 0.82 | KCNH2 (0.49) | KCNH2 | |
| SCHEMBL3016312 | 0.80 | KCNH2 (0.54) | KCNH2 | |
| SCHEMBL3022635 | 0.76 | MTNR1A (0.36) | KCNH2 | |
| SCHEMBL3013743 | 0.74 | DRD2 (0.37) | KCNH2 | |
| Hydrochloric Acid SCHEMBL3008614 | 0.73 | DRD2 (0.36) | KCNH2 | |
| SCHEMBL13213628 | 0.73 | KCNH2 (0.60) | KCNH2 | |
| Hydrochloric Acid SCHEMBL3020232 | 0.72 | KCNH2 (0.60) | KCNH2 | |
| SCHEMBL3720551 | 0.70 | KCNH2 (0.49) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100197679-A1 | COMPOUNDS | GLAXO GROUP LIMITED | 2010-08-05 | — | — | US | claimed |
| EP-2139898-A1 | COMPOUNDS | Glaxo Group Limited (GB) | 2010-01-06 | — | — | EP | claimed |
| WO-2008128961-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-10-30 | — | — | WO | claimed |
| US-20100197679-A1 | COMPOUNDS | GLAXO GROUP LIMITED | 2010-08-05 | — | — | US | disclosed |
| US-20100197679-A1 | COMPOUNDS | GLAXO GROUP LIMITED | 2010-08-05 | — | — | US | disclosed |
| US-20100197679-A1 | COMPOUNDS | GLAXO GROUP LIMITED | 2010-08-05 | — | — | US | disclosed |
| EP-2139898-A1 | COMPOUNDS | Glaxo Group Limited (GB) | 2010-01-06 | — | — | EP | disclosed |
| WO-2008128961-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-10-30 | — | — | WO | disclosed |
| WO-2008128961-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197679-A1 | COMPOUNDS | NRDC, MRPL21, NISCH | KCNH2 2445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.